Novo Nordisk is attempting to block exports of a Russian-made generic version of its blockbuster drug Ozempic (semaglutide), a move that signals growing concern over market competition. The Russian generic, produced by Geropharm, has been available for two years and is rapidly gaining traction.
Pharmacy sales of semaglutide-based medications in Russia nearly tripled between the first nine months of 2024 and 2025, reaching 13 billion roubles (approximately $165 million), according to data from Russian analytical firm DSM Group. Novo Nordisk’s original Ozempic held only a 3% share of the Russian market last year, having been displaced by the more affordable generic.
This year, Geropharm expanded its reach, launching the generic semaglutide in Kazakhstan, Azerbaijan, and Paraguay. Analysts in Russia suggest Novo Nordisk fears losing market share in key international territories as a result of this increased competition.
Generic Ozempic’s Global Expansion Raises Concerns for Novo Nordisk
The Danish pharmaceutical giant is reportedly working to halt exports of a Russian-made semaglutide generic, potentially impacting access to the medication in several countries.
- Novo Nordisk is trying to prevent the export of a Russian Ozempic generic.
- The Russian generic has significantly increased market share within Russia.
- Geropharm has expanded sales of the generic into Kazakhstan, Azerbaijan, and Paraguay.
- Analysts believe Novo Nordisk is concerned about losing customers in key foreign markets.
What is driving Novo Nordisk’s actions? The company’s efforts to restrict exports of the Russian generic stem from a desire to protect its market position and revenue streams, particularly as more affordable alternatives become available globally.
Did you know? Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity.
The rise of the Russian generic highlights a broader trend in the pharmaceutical industry: the increasing availability of biosimilars and generics that challenge the dominance of branded drugs. This competition can lead to lower prices and increased access to essential medications, but also raises concerns for companies like Novo Nordisk that rely on patent protection and brand recognition.
The situation is particularly noteworthy given the geopolitical context. The availability of a domestically produced generic in Russia has become more important since the departure of many Western pharmaceutical companies following international sanctions.
